Among them is Assembly Biosciences' ABIH-0731, which received a Fast Track designation from the FDA, HEC Pharm's GLS-4, and Johnson & Johnson's JNJ-6379, which both target the HBV capsid, Ionis' IONIS-HBVLRx, an antisense oligonucleotide in clinical trials in China and Japan, and Gilead's GS-9688, a toll like receptor 8 (TLR-8) agonist. Gilead Sciences is the only company that has a solid presence in HBV with its brands Viread and Vemlidy, as well as a strong pipeline featuring 36 active clinical trials. Rosenbaum adds "GlobalData's primary and secondary research have identified a high unmet need in the finite duration of treatment with oral therapies.